Business Impacts of Terrorism, War, Epidemics, Disasters and Other Events
First written in FY2016. 4 of 8 entries say "Materialised", first in FY2018-Q3. Latest entry: FY2022-Q2.
Terumo moved to the "Worse" side of this theme in 2020, the same year as the typical company in this theme.
The whole theme swung hardest in 2020: 15 of 22 companies on the "Worse" side.
3 other companies' latest entry also says "Mitigated".
- FY2022-Q2MitigatedAnnual report
「The impact of the COVID-19 outbreak that began in the previous fiscal year was substantially alleviated, particularly in North America and Europe, and healthcare demand recovered as COVID-19 vaccines became more widely available, elective procedures that had been postponed across various medical specialties were performed, and tests, diagnoses and hospital admissions increased.」
Although the business impact of the epidemic has continued, healthcare demand recovered in North America and Europe as vaccines became more widely available, and the impact eased compared with the previous quarter. - FY2021WorsenedAnnual report
「The impact of the spread of COVID-19 is also expected in FY2021.」
The risk of epidemics and infectious diseases was described as continuing to affect not only FY2021 results but also the fiscal year ending March 2022. - FY2021-Q3MaterialisedAnnual report
「From October to December, COVID-19 infections resurged, particularly in Europe and the Americas, but the impact on healthcare provider operations was limited.」
The risk of epidemics and infectious diseases materialized in the form of a resurgence in COVID-19 infections in Europe and the Americas. It was explained, however, that the impact on healthcare provider operations was limited. - FY2021-Q1MaterialisedAnnual report
「Results for the cumulative first quarter of the current consolidated fiscal year were as follows. Sales revenue was ¥131.3 billion, down 13.9% year on year.」
The impact of the COVID-19 outbreak on business materialized in FY2021-Q1 as a 13.9% year-on-year decline in consolidated sales revenue. - FY2020MaterialisedAnnual report
「Although some regions were affected by the spread of COVID-19 in the fourth quarter, results exceeded the initial profit forecast for the fiscal year.」
Regarding risks from epidemics and infectious diseases, the spread of COVID-19 actually affected demand and business activities in some regions. The disclosure also describes measures including business continuity planning, stable supply and ensuring liquidity. - FY2018MitigatedAnnual report
「At the production subsidiary in the Commonwealth of Puerto Rico, production of the Angio-Seal hemostasis device was suspended from 20 September due to the impact of a hurricane, resumed in November, and shipments began in January 2018.」
Production resumed in November after the hurricane-related suspension, and shipments began in January 2018. - FY2018-Q3MaterialisedAnnual report
「At the production subsidiary in the US territory of Puerto Rico, production of the Angio-Seal hemostasis device had been suspended from 20 September due to the impact of a hurricane, but resumed in November, with shipments beginning in January of Heisei 30.」
A hurricane caused the production activities of the Puerto Rico production subsidiary to cease from 20 September. Production subsequently resumed in November, and shipments began in January 2018. - FY2016First statedAnnual report
「Changes in business practices, terrorism, war, epidemics, global outbreaks of infectious diseases such as novel influenza, natural disasters and other events could affect the Company's operating results and financial condition.」
The Company routinely discloses risks from other external shocks.